Literature DB >> 9570509

Regulation of equine infectious anemia virus expression.

W Maury1.   

Abstract

Equine infectious anemia virus (EIAV) is an ungulate lentivirus that is related to human immunodeficiency virus (HIV). Much of the understanding of lentiviral gene regulation comes from studies using HIV. HIV studies have provided insights into molecular regulation of EIAV expression; however, much of the regulation of EIAV expression stands in stark contrast to that of HIV. This review provides an overview of the current state of knowledge of EIAV regulation by comparing and contrasting EIAV gene regulation to HIV. The role of EIAV gene regulation is discussed in relation to EIAV pathogenesis.

Entities:  

Mesh:

Year:  1998        PMID: 9570509     DOI: 10.1007/BF02253351

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  9 in total

1.  Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments.

Authors:  Tim van Opijnen; Maarten C Boerlijst; Ben Berkhout
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars.

Authors:  Mary Poss; Howard Ross
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

3.  Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1.

Authors:  R Taube; K Fujinaga; D Irwin; J Wimmer; M Geyer; B M Peterlin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Structure of equine infectious anemia virus matrix protein.

Authors:  Hideki Hatanaka; Oleg Iourin; Zihe Rao; Elizabeth Fry; Alan Kingsman; David I Stuart
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.

Authors:  R E Jeeninga; M Hoogenkamp; M Armand-Ugon; M de Baar; K Verhoef; B Berkhout
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site.

Authors:  K Verhoef; R W Sanders; V Fontaine; S Kitajima; B Berkhout
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner.

Authors:  Tim van Opijnen; Rienk E Jeeninga; Maarten C Boerlijst; Georgios P Pollakis; Veera Zetterberg; Mika Salminen; Ben Berkhout
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 9.  Gene Therapy of ABCA4-Associated Diseases.

Authors:  Alberto Auricchio; Ivana Trapani; Rando Allikmets
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-08       Impact factor: 6.915

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.